Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Shanghai INT Medical Instruments Co., Ltd.*

上海瑛泰醫療器械股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1501)

(1) RESIGNATION OF DIRECTORS
(2) PROPOSED APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTORS
(3) ELECTION OF EMPLOYEE REPRESENTATIVE DIRECTOR
(4) CHANGE IN COMPOSITION OF BOARD COMMITTEES
(5) PROPOSED AUTHORIZATION TO THE BOARD TO GRANT AWARDS TO DR. LIANG UNDER THE H SHARE AWARD AND TRUST SCHEME
(6) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND
(7) PROPOSED AMENDMENTS TO THE RULES OF PROCEDURES FOR THE BOARD

I. RESIGNATION OF DIRECTORS

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The Board hereby announces that Mr. Wang Ruiqin ("**Mr. Wang**") has tendered his resignation as a non-executive Director of the Company due to personal work adjustment, with effect from 24 August 2026, being the date on which the Company received the notice of resignation.

Mr. Wang has confirmed that he has no disagreement with the Board and that there are no matters in relation to his resignation that need to be brought to the attention of the Shareholders and the Stock Exchange.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Wang for his valuable contribution to the Company during his tenure of office.

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTORS

Mr. Jian Xigao ("**Mr. Jian**") and Mr. Hui Hung Kwan ("**Mr. Hui**") have served as independent non-executive Directors of the Company since 8 December 2018, and have now served in their positions for more than seven consecutive years. Currently, the Company is preparing for its initial public offering of Renminbi-denominated ordinary shares (A shares) and listing. In accordance with the provisions of A share related laws and regulations including the Measures for the Administration of Independent Directors of Listed Companies, independent non-executive Directors may not serve for more than six consecutive years. Given that the consecutive tenure of Mr. Jian and Mr. Hui has exceeded the maximum limit set forth in the aforementioned A-share regulatory requirements, to comply with the regulatory requirements for A share listing, and in light of adjustments to their personal work schedules, Mr. Jian and Mr. Hui have applied to resign from their respective positions as independent non-executive Directors of the Company and members of the special committees of the Board.

Given that the resignations of Mr. Jian and Mr. Hui will result in the number of independent non-executive Directors on the Company's Board falling below the statutory number of the Articles of Association, pursuant to the relevant provisions of the Company Law and the Articles of Association, Mr. Jian and Mr. Hui will continue to perform their duties for their respective positions as independent non-executive Directors and members of the special committees of the Board in accordance with applicable laws, administrative regulations, normative documents and the Articles of Association until the new independent non-executive Directors are elected and duly appointed at the EGM. The resignation of Mr. Jian and Mr. Hui will take effect from the date on which the new independent non-executive Directors officially take office.

Both Mr. Jian and Mr. Hui have confirmed that they have no disagreement with the Company and the Board and that there are no other matters in relation to their resignations that need to be brought to the attention of the Shareholders and the Stock Exchange.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Jian and Mr. Hui for their valuable contributions to the Company during their respective tenure of office.

II. PROPOSED APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTORS

The Board is pleased to announce that, after considering the recommendations of the Nomination Committee, the Board has resolved to propose the appointments of Dr. Zhang Peng ("**Dr. Zhang**") and Dr. Lai Wan-lung ("**Dr. Lai**") as candidates for independent non-executive Directors of the Fourth Session of the Board (the "**Proposed Appointment of Independent Non-Executive Directors**"). The Proposed Appointment of Independent Non-Executive Directors are subject to approval by the Shareholders by way of an ordinary resolution at the EGM and will take effect from the date of such approval at the EGM.

(1) Biographical Details of Dr. Zhang

Dr. Zhang Peng, aged 59. Dr. Zhang currently serves as a chief physician at the treatment and diagnostic center of interventional radiology department at Xuanwu Hospital Capital Medical University, the director and chief expert of the cerebrovascular disease center at Fujian Provincial Hospital, the director of the cerebrovascular disease diagnosis and treatment center at Heze Municipal Hospital, the vice chair of the interventional neuroradiology professional committee of the interventional radiology branch of the Chinese Society of Radiology, a member of the endovascular therapy working group of the Chinese Neurosurgical Society, a standing member of the neurointerventional professional committee of the Chinese Medical Doctor Association, a member of the neurology professional committee of the interventional branch under the Chinese Medical Doctor Association, a member of the neurointerventional branch of the Beijing Medical Association* (北京市醫學會) and a senior member of the World Federation of Neurointerventional Radiology* (世界神經介入放射聯合會). Dr. Zhang obtained a bachelor's degree in English-taught medicine from Shandong Medical University in July 1991, and a Ph.D. in surgery from China Union Medical University* (中國協和醫科大學) in July 2001.

Dr. Zhang was nominated as a candidate for the independent non-executive Director by the Shareholders and was approved following review by the Nomination Committee. Subject to the approval of appointment of Dr. Zhang as an independent non-executive Director by the Shareholders at the EGM, the Company will enter into a service contract with Dr. Zhang. The term of office of Dr. Zhang will commence from the date of approval of his appointment at the EGM until the date of expiry of the Fourth Session of the Board, and is subject to re-election upon expiry of his term of office. Dr. Zhang's director's remuneration is proposed to be RMB120,000 per year (before tax), which has been determined by the Board based on the recommendations of the Remuneration Committee with reference to his duties and responsibilities as well as prevailing market conditions, and will be subject to review by the Remuneration Committee from time to time.

Dr. Zhang has confirmed that (i) he satisfies each of the independence factors as set out in Rule 3.13 of the Listing Rules; (ii) he has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as defined under the Listing Rules) of the Company; and (iii) there are no other factors that may affect his independence as of the date of this announcement. Save as disclosed above, as at the date of this announcement, Dr. Zhang (i) does not hold any positions within the Company or other members of the Group; (ii) does not hold any directorship in any listed public companies, the securities of which are listed on any securities market in Hong Kong or overseas, over the past three years; (iii) does not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders of the Company; and (iv) does not have any interest or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations. There is no other information in relation to the proposed appointment of Dr. Zhang that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules nor is there any other matter that needs to be brought to the attention of the Shareholders.

(2) Biographical Details of Dr. Lai

Dr. Lai Wan-lung, aged 58, currently serves as the Managing Director of master's program in international banking and finance of Lingnan University ("**LU**"). Dr. Lai possesses governance experience in various administrative units. Specifically, he served as a member of the Council of LU, the Court of LU and the Board of Governors of the LU Institute of Further Education, respectively, and served for the campus development and management committee as well as the investment group. During the period from 2016 to 2019, he concurrently served as the founding associate director of the Graduate Faculty* (研究生部) (now known as the School of Graduate Studies), where he was responsible for developing graduate programs for the university, and also concurrently served as the director of master's program in international higher education and management. In the field of finance, Dr. Lai is a founding member and distinguished Senior Fellow of the Hong Kong Securities and Investment Institute, where he served as a member of the units such as the Examinations Committee and the Group for Review of Misconduct Policy* (不當行為政策檢討小組). He also served as a member of the talent readiness working group of the Financial Services Development Council. Dr. Lai successively obtained his bachelor's degree and Ph.D. in finance from Arizona State University in the United States in 1990 and 1995, respectively.

Dr. Lai was nominated as a candidate for independent non-executive Director by the Shareholders and was approved following review by the Nomination Committee. Subject to the approval of appointment of Dr. Lai as an independent non-executive Director by the Shareholders at the EGM, the Company will enter into a service contract with Dr. Lai. The term of office of Dr. Lai will commence from the date of approval of his appointment at the EGM until the date of expiry of the Fourth Session of the Board, and is subject to re-election upon expiry of his term of office. Dr. Lai's director's remuneration is proposed to be RMB120,000 per year (before tax), which has been determined by the Board based on the recommendations of the Remuneration Committee with reference to his duties and responsibilities as well as prevailing market conditions, and will be subject to review by the Remuneration Committee from time to time.

Dr. Lai has confirmed that (i) he satisfies each of the independence factors as set out in Rule 3.13 of the Listing Rules; (ii) he has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as defined under the Listing Rules) of the Company; and (iii) there are no other factors that may affect his independence as of the date of this announcement. Save as disclosed above, as at the date of this announcement, Dr. Lai (i) does not hold any positions within the Company or other members of the Group; (ii) does not hold any directorship in any listed public companies, the securities of which are listed on any securities market in Hong Kong or overseas, over the past three years; (iii) does not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders of the Company; and (iv) does not have any interest or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations. There is no other information in relation to the proposed appointment of Dr. Lai that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules nor is there any other matter that needs to be brought to the attention of the Shareholders.

III. ELECTION OF EMPLOYEE REPRESENTATIVE DIRECTOR

Pursuant to the provisions of the Articles of Association, the Company convened the eleventh meeting of the second session of the employee representative meeting on 24 August 2026, at which Ms. Chen Jie ("**Ms. Chen**") was elected as the employee representative Director of the Fourth Session of the Board (the "**Employee Representative Director**"), and she will form the Fourth Session of the Board with other Directors, with a term commencing from the date of Ms. Chen's election until the date of expiry of the Fourth Session of the Board.

Biographical details of Ms. Chen are set out as follows:

Ms. Chen Jie, aged 44. Ms. Chen served as an accountant in Shanghai Sieton (Group) Co., Ltd. (上海協通(集團)有限公司) from July 2004 to March 2007. Ms. Chen joined the Company as the manager of the administrative department in December 2008. Moreover, Ms. Chen has been the supervisor of Shanghai Qimu Medical Instruments Co., Ltd.* (上海七木醫療器械有限公司), Shanghai Puhui Medical Instruments Co., Ltd.* (上海璞慧醫療器械有限公司), Shanghai Healing Medical Instruments Co., Ltd.* (上海翰淩醫療器械有限公司), Shandong INT Medical Instruments Co., Ltd.* (山東瑛泰醫療器械有限公司), Shanghai Puyue Medical Instruments Co., Ltd.* (上海璞躍醫療器械有限公司), Shandong Insant New Materials Co., Ltd.* (山東瑛盛新材料有限公司), Zhuhai Puyue Medical Instruments Co., Ltd.* (珠海璞躍醫療器械有限公司), Shandong INT Medical Technology Co., Ltd.* (山東瑛泰醫療科技有限公司) and Shanghai INT Property Management Co., Ltd.* (上海瑛泰實業有限公司) since August 2018, November 2018, February 2019, January 2021, March 2021, March 2023, September 2023, October 2024 and April 2025 respectively, and has been the director of Shanghai Pukon Medical Instruments Co., Ltd.* (上海璞康醫療器械有限公司) since February 2020. Ms. Chen had been the employee representative supervisor of the Company from May 2022 to May 2026, and the supervisor of Shanghai INT Biotechnology Co., Ltd.* (上海瑛泰生物科技有限公司) from September 2022 to May 2026. Ms. Chen obtained an associate degree in accounting from Shanghai Lixin University of Accounting and Finance (formerly known as Shanghai Lixin Institute of Commerce) in Shanghai, the PRC in July 2004 and a bachelor's degree from Tongji University in Shanghai, the PRC in January 2011. Ms. Chen received a preliminary-level accounting qualification accredited by the Ministry of Finance of the PRC in May 2006.

Ms. Chen will not receive any Directors' emoluments or allowance during the term of office for serving as the Employee Representative Director.

As at the date of this announcement, Ms. Chen is deemed to be interested in 126,700 H Shares within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), representing approximately 0.06% of the total number of issued shares of the Company, comprising 100,000 H Shares indirectly held by Ms. Chen and 26,700 restricted shares granted to her under the Share Incentive Scheme.

Save as disclosed above, as at the date of this announcement, Ms. Chen (i) does not hold any positions within the Company or other members of the Group; (ii) does not hold any directorship in any listed public companies, the securities of which are listed on any securities market in Hong Kong or overseas, over the past three years; (iii) does not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders of the Company; and (iv) does not have any interest or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations. There is no other information that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules nor is there any other matter that needs to be brought to the attention of the Shareholders.

IV. CHANGE IN COMPOSITION OF BOARD COMMITTEES

The Board hereby announces that, subject to approval by the Shareholders at the EGM of the Proposed Appointment of Independent Non-Executive Directors, the following changes will be made to the composition of special committees of the Board:

(i) Audit Committee: Mr. Xu Congli will be appointed as the chairman, Dr. Lai (subject to his appointment becoming effective) and Ms. Chen will be appointed as the members, Mr. Hui will no longer serve as the chairman, and Dr. Song Yuan will no longer serve as a member;

(ii) Remuneration Committee: Dr. Lai (subject to his appointment becoming effective) will be appointed as the chairman, Mr. Xu Congli will be appointed as a member, Mr. Jian will no longer serve as the chairman, and Mr. Hui will no longer serve as a member;

(iii) Nomination Committee: Dr. Zhang (subject to his appointment becoming effective) will be appointed as the chairman, Mr. Xu Congli will be appointed as a member, and Mr. Jian will no longer serve as a member; and

(iv) Strategy and Sustainability Committee: The Board has resolved to establish the Strategy and Sustainability Committee with Dr. Liang as the chairman, Dr. Zhang (subject to his appointment becoming effective) and Dr. Lai (subject to his appointment becoming effective) as members.

V. PROPOSED AUTHORIZATION TO THE BOARD TO GRANT AWARDS TO DR. LIANG UNDER THE H SHARE AWARD AND TRUST SCHEME

References are made to the Company's announcements dated 18 March 2022 and 16 May 2022, and the circular dated 12 April 2022 in relation to, among others, the proposal and approval to adopt the H Share Award and Trust Scheme. Under the H Share Award and Trust Scheme, the Company has appointed the Trustee to acquire up to 10,420,000 H Shares (the "**Scheme Limit**") at the prevailing market prices for the H Share Award and Trust Scheme.

As at the date of this announcement, the Company had a total of 211,200,000 issued H Shares (excluding treasury shares, if any), and the Trustee had purchased an aggregate of 4,356,400 H Shares, representing approximately 41.81% of the maximum number of H Shares available for purchase under the H Share Award and Trust Scheme. On 28 June 2026, the Company granted 33,400 H Share award shares, representing approximately 0.016% of the total issued Shares, to Dr. Liang under the H Share Award and Trust Scheme. Immediately after the completion of such grant, as at the date of this announcement, the number of award shares held by the Trustee and available for future grants under the H Share Award and Trust Scheme was 4,323,000 H Shares, representing approximately 2.05% of the total issued Shares.

Given that Dr. Liang, as the chairman, an executive Director and the general manager of the Company, plays a core leadership role in the Group's business development and the formulation and implementation of its long-term strategy, the Board believes that granting award shares to Dr. Liang will help further align his personal interests with those of the Company and the Shareholders as a whole, thereby promoting the Company's sustainable development. At the forthcoming EGM, the Board will propose an ordinary resolution to the Shareholders to consider and approve the authorization to the Board to grant awards to Dr. Liang under the H Share Award and Trust Scheme, with specific grant scheme and matters as follows:

1. Grantee: Dr. Liang, the chairman, an executive Director and the general manager of the Company.

2. Number of shares granted: Not exceeding 50% of the Scheme Limit, i.e. 5,210,000 H Shares, representing approximately 2.47% of the total issued Shares as of the date of this announcement.

3. Price of shares granted: To be determined based on the actual transaction costs incurred by the Trustee for the acquisition of such H Shares.

4. Vesting period:

Tranche	**Vesting schedule**	**Vesting ratio**
The first tranche	12 months from the date of grant	0%
The second tranche	24 months from the date of grant	30%
The third tranche	36 months from the date of grant	70%

5. Vesting conditions:

   (1) Conditions of the services: For a period of 36 months from the date of grant, the participant must be an employee who has signed an employment contract with the Company or any of its subsidiaries and who has not resigned, had their employment terminated by mutual agreement, or been dismissed.

   (2) Performance assessment indicators of the Company: To be determined based on the operating performance assessment indicators approved by the Board at the time of grant.

   (3) Individual performance assessment indicators: The individual performance assessment result of the corresponding assessment year reaches the qualified level or above.

   If any of the above conditions are not met, the award shares for that tranche shall immediately become void, be forfeited free of charge, and shall not be vested.

6. Clawback mechanism: In the event that the participant engages in acts that are detrimental to the core interests of the Company or commits gross violations of laws and regulations resulting in economic or reputational losses to the Company during his term of office, the Company shall have the right to forfeit in full all vested award shares or the economic benefits derived therefrom, which shall be returned to the Company to compensate for the relevant losses of the Company.

7. Source of award shares: The relevant shares proposed to vest in the participant (subject to vesting conditions) shall be H Shares purchased by the Trustee on the market under the H Share Award and Trust Scheme as directed by the Board and/or its authorized persons.

Implications under the Listing Rules

The H Share Award and Trust Scheme involves only the purchasing by the Trustee of existing H Shares through on-market transactions on the Stock Exchange, and no new Shares will be issued, nor will any options over new securities be granted, under the H Share Award and Trust Scheme. Therefore, the H Share Award and Trust Scheme will constitute a share scheme involving existing Shares under Chapter 17 of the Listing Rules, and will be subject to the applicable provisions under Rule 17.12 of the Listing Rules. However, pursuant to Article 15.2 of the H Share Award and Trust Scheme, the total number of non-vested award shares granted to a selected participant under the Scheme shall not exceed 1% of the total issued H Shares of the Company from time to time. As such, the resolution on proposed authorization to the Board to grant awards to Dr. Liang under the H Share Award and Trust Scheme constitutes an amendment to the terms of the H Share Award and Trust Scheme, which is subject to the Shareholders' approval at a general meeting of the Company pursuant to the provisions of the Articles of Association and the H Share Award and Trust Scheme.

Given that the H Share Award and Trust Scheme is designed to motivate, reward and retain talents, and to encourage them to continue to contribute to the Company's long-term growth, profitability and value enhancement, the Board (including independent non-executive Directors) believes that the grant of awards to Dr. Liang under the Scheme will be conducive to the Company's sustainable development and is in the interests of the Company and the Shareholders as a whole.

VI. PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

In light of the Company's future strategic development needs, the Board proposes to amend the Articles of Association to reflect matters such as the addition of Employee Representative Director and the establishment of the Strategy and Sustainability Committee, and intends to seek Shareholders' approval for the aforementioned amendments to the Articles of Association at the forthcoming EGM. Except for the proposed amendments, the other provisions of the Articles of Association remain unchanged. Details of the proposed amendments to the Articles of Association will be set forth in the circular of the EGM.

VII. PROPOSED AMENDMENTS TO THE RULES OF PROCEDURES FOR THE BOARD

In order to further enhance the Company's level of standardized operations and improve its corporate governance structure, taking into account the Company's actual circumstances, the Board proposes to amend the Rules of Procedures for the Board to reflect matters such as the addition of Employee Representative Director and the establishment of the Strategy and Sustainability Committee, and intends to seek Shareholders' approval for the aforementioned amendments to the Rules of Procedures for the Board at the forthcoming EGM. Except for the proposed amendments, the other provisions of the Rules of Procedures for the Board remain unchanged. Details of the proposed amendments to the Rules of Procedures for the Board will be set forth in the circular for the Company's EGM.

EGM

The Company will convene an EGM at which it will propose resolutions regarding items II, V, VI and VII above to seek Shareholders' approval. A circular containing, among others, details of the aforementioned resolutions and the notice of the EGM, will be published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.int-medical.com) in due course, and will be despatched to the Shareholders in accordance with the means of receiving corporate communications elected by the Shareholders.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following expressions shall have the following meanings:

"Articles of Association"	the articles of association of the Company, as amended, modified or otherwise supplemented from time to time
"Audit Committee"	the audit committee of the Board
"Board" or "Board of Directors"	the board of Directors
"Company"	Shanghai INT Medical Instruments Co., Ltd.* (上海瑛泰醫療器械股份有限公司), a joint stock company incorporated in the PRC with limited liability, the H Shares of which are listed on the Stock Exchange (stock code: 1501)
"Director(s)"	the director(s) of the Company
"Dr. Liang"	Dr. Liang Dongke, the Chairman, an executive Director and general manager of the Company
"EGM"	the 2026 first extraordinary general meeting of the Company or any adjournment thereof (as the case may be) to be convened at Block 2, No. 925 Jin Yuan Yi Road, Jiading District, Shanghai, the PRC at 2:00 p.m. on Thursday, 24 September 2026
"Group"	the Company and its subsidiaries
"H Share(s)"	overseas listed foreign invested ordinary share(s) in the share capital of the Company, with a nominal value of RMB1.00 each, listed on the Main Board of the Stock Exchange
"H Share Award and Trust Scheme" or "Scheme"	the H Share award and trust scheme of the Company approved by the Board on 18 March 2022 and approved by the Shareholders on 16 May 2022 for adoption

"Hong Kong"	the Hong Kong Special Administrative Region of the PRC
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange, as amended or supplemented from time to time
"Nomination Committee"	the nomination committee of the Board
"PRC"	the People's Republic of China but excluding, for the purposes of this announcement only, Hong Kong, Macau Special Administrative Region of the People's Republic of China and Taiwan region
"PRC Company Law"	the Company Law of the People's Republic of China, as the same may be amended, supplemented or otherwise modified from time to time
"Remuneration Committee"	the remuneration committee of the Board
"RMB"	Renminbi, the lawful currency of the PRC
"Rules of Procedures for the Board"	the rules of procedures for the Board of the Company, as amended, modified or otherwise supplemented from time to time
"Share(s)"	H Share(s)
"Shareholder(s)"	the holder(s) of the Share(s)
"Share Incentive Scheme"	the share incentive scheme approved by the Shareholders on 17 December 2020 and the amendments to the Share Incentive Scheme approved by the Shareholders on 17 May 2021
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"Strategy and Sustainability Committee"	the strategy and sustainability committee of the Board
"Trustee"	Trident Trust Company (HK) Limited, being the trustee of the H Share Award and Trust Scheme

"treasury shares"	has the meaning ascribed to it under the Listing Rules
"%"	per cent

By order of the Board
Shanghai INT Medical Instruments Co., Ltd.*
上海瑛泰醫療器械股份有限公司
Dr. Liang Dongke
Chairman

Shanghai, the PRC
24 August 2026

As at the date of this announcement, the Board comprises Dr. Liang Dongke and Mr. Lin Sen as executive Directors, Dr. Song Yuan, Ms. Chen Hongqin, Mr. Zhang Hong and Ms. Chen Jie (employee representative Director) as non-executive Directors, Mr. Jian Xigao, Mr. Hui Hung Kwan and Mr. Xu Congli as independent non-executive Directors.

* *For identification purposes only*